Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DS-3201b in healthy Japanese subjects
jRCT2080223748Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of valemetostat in cancer (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Pharmacokinetics of DS-3201a after single oral administration of DS-3201b, Relative bioavailability of DS-3201b tablet vs capsule formulations and 1 more.
02
Drugs
valemetostat
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223748.